Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Segesterone acetate + testosterone is a transdermal gel formulation under development by the Population Council and the National Institute of Child Health and Human Development (NICHD) as a male hormonal contraceptive. The combination consists of segesterone acetate (Nestorone), a potent progestin that acts as a progesterone receptor agonist to suppress the hypothalamic-pituitary-gonadal axis, and testosterone to maintain physiological androgen levels. By inhibiting the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), the gel effectively suppresses spermatogenesis. The daily, self-administered topical application is designed to provide a reversible and effective contraceptive method for men with fewer side effects than injectable alternatives.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on segesterone acetate + testosterone.